IE87241B1 - Prevention and/or treatment of neurodegenerative disease - Google Patents
Prevention and/or treatment of neurodegenerative disease Download PDFInfo
- Publication number
- IE87241B1 IE87241B1 IE20180146A IE20180146A IE87241B1 IE 87241 B1 IE87241 B1 IE 87241B1 IE 20180146 A IE20180146 A IE 20180146A IE 20180146 A IE20180146 A IE 20180146A IE 87241 B1 IE87241 B1 IE 87241B1
- Authority
- IE
- Ireland
- Prior art keywords
- composition
- composition according
- zeaxanthin
- omega
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE20180146A1 IE20180146A1 (en) | 2019-06-12 |
| IE87241B1 true IE87241B1 (en) | 2021-07-07 |
Family
ID=60950313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20180146A IE87241B1 (en) | 2017-12-04 | 2018-05-15 | Prevention and/or treatment of neurodegenerative disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10835509B2 (enExample) |
| EP (2) | EP4599891A3 (enExample) |
| JP (1) | JP2021505527A (enExample) |
| KR (1) | KR20200095452A (enExample) |
| AU (1) | AU2018379644B2 (enExample) |
| BR (1) | BR112020005132A2 (enExample) |
| CA (1) | CA3071786C (enExample) |
| ES (1) | ES3047101T3 (enExample) |
| GB (2) | GB201720119D0 (enExample) |
| IE (1) | IE87241B1 (enExample) |
| MX (1) | MX2020002458A (enExample) |
| RU (1) | RU2020111305A (enExample) |
| SG (1) | SG11202000786RA (enExample) |
| WO (1) | WO2019110951A1 (enExample) |
| ZA (1) | ZA202000558B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
| US12076299B2 (en) | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
| TW202313075A (zh) * | 2021-05-17 | 2023-04-01 | 日商小野藥品工業股份有限公司 | 用於改善認知功能之組合物 |
| CN120417894A (zh) * | 2022-12-26 | 2025-08-01 | 三得利控股株式会社 | 脑神经细胞保护用组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| EP2219478B1 (en) * | 2007-12-17 | 2017-05-10 | Newtricious B.V. | Method of producing egg yolk based functional food product and products obtainable thereby |
| GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| ES2675905T3 (es) * | 2011-07-07 | 2018-07-13 | Howard Foundation Holdings Limited | Método para mejorar la discapacidad por deslumbramiento |
| DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
| GB201300055D0 (en) * | 2013-01-03 | 2013-02-20 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
| US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
| HK1211836A1 (en) * | 2013-03-28 | 2016-06-03 | Omniactive Health Technologies Limited | Neuroprotective effect of carotenoids in brain |
| WO2015005443A1 (ja) * | 2013-07-10 | 2015-01-15 | ライオン株式会社 | 内服組成物 |
| EP3419439B1 (en) * | 2016-02-22 | 2020-04-08 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 JP JP2020521460A patent/JP2021505527A/ja active Pending
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 EP EP25186112.6A patent/EP4599891A3/en active Pending
- 2018-05-10 ES ES18725605T patent/ES3047101T3/es active Active
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en not_active Ceased
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko active Pending
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 EP EP18725605.2A patent/EP3644979B1/en active Active
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3071786A1 (en) | 2019-06-13 |
| WO2019110951A1 (en) | 2019-06-13 |
| US10835509B2 (en) | 2020-11-17 |
| AU2018379644A1 (en) | 2020-03-19 |
| KR20200095452A (ko) | 2020-08-10 |
| ES3047101T3 (en) | 2025-12-03 |
| EP3644979B1 (en) | 2025-08-06 |
| AU2018379644B2 (en) | 2024-02-08 |
| GB201720119D0 (en) | 2018-01-17 |
| US20190167624A1 (en) | 2019-06-06 |
| RU2020111305A (ru) | 2022-01-10 |
| GB2568986B (en) | 2019-12-18 |
| BR112020005132A2 (pt) | 2020-09-15 |
| NZ761512A (en) | 2024-01-26 |
| JP2021505527A (ja) | 2021-02-18 |
| GB201807590D0 (en) | 2018-06-27 |
| ZA202000558B (en) | 2021-10-27 |
| GB2568986A (en) | 2019-06-05 |
| IE20180146A1 (en) | 2019-06-12 |
| CA3071786C (en) | 2023-11-14 |
| MX2020002458A (es) | 2020-07-20 |
| EP4599891A3 (en) | 2025-10-22 |
| EP3644979A1 (en) | 2020-05-06 |
| SG11202000786RA (en) | 2020-06-29 |
| EP4599891A2 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103533921B (zh) | 用于治疗神经外伤的方法 | |
| ES2955713T3 (es) | Agente de mejora de la función visual, y método para mejorar la función visual | |
| US20130108706A1 (en) | Dietary formulations | |
| CN105163731B (zh) | 内服组合物 | |
| IE87241B1 (en) | Prevention and/or treatment of neurodegenerative disease | |
| US10881638B2 (en) | Eye health composition | |
| HUE028065T2 (en) | Preparations for the treatment of neurological disorders | |
| CN101327199A (zh) | 作为抗高血压药的类胡萝卜素 | |
| US12053437B2 (en) | Eye health supplement | |
| JP2014208600A (ja) | ウコン中の有用成分を含有する組成物 | |
| JP4818637B2 (ja) | 低密度リポタンパク質（ｌｄｌ）酸化抑制剤 | |
| WO2013086330A1 (en) | Nutritional compositions comprising curcumin and docosahexaenoic acid for improving cognition | |
| Parker | Glaucoma-evidence for adjunctive management: Part 1 cellular and physiological level | |
| US20210228557A1 (en) | Therapeutic compositions comprising coenzyme q10 | |
| Kelly et al. | Integrative Approaches to Cognitive Decline | |
| CN106659707A (zh) | 红细胞功能提高剂 | |
| Gillingham | Omega-3 fatty acids and the menopausal transition: clinical efficacy in depression and beyond | |
| Harper | A healthy diet to reduce the risk of dementia in people with a learning disability | |
| JP2016008214A (ja) | Ｄｈａ、ｅｐａにアスタキサンチンを含有した機能性食品、及び錠剤又はカプセル錠剤。 |